Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00297011 · ClinicalTrials.gov registry record · Phase 2
Valacyclovir+Temovate Gel for the Treatment of Herpes Labialis
A Phase 2 study of Herpes Labialis, sponsored by University of Utah.
- Completed
- Registry status
- Phase 2
- Development phase
- 300
- Enrollment target
- 1
- Study location
NCT00297011 is a Phase 2 study of Herpes Labialis that has completed, run by University of Utah. The registered enrollment target is 300 participants, below the 1,013-participant average among 6 other Herpes Labialis trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00297011, a Phase 2 study of Herpes Labialis, has completed, sponsored by University of Utah.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
A randomized study comparing the combination of valacyclovir and temovate gel (clobetasol gel) versus placebo for the treatment of recurrent herpes labialis (cold sores).
Conditions Studied
Interventions
- DRUG valacyclovir+clobetasol gel
Study Locations (1)
Utah
- University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2004-09 |
| Est. Completion | 2008-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00297011
The ClinicalTrials.gov registry entry for NCT00297011 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,013-participant average among 6 other Herpes Labialis trials with a reported enrollment target (70% lower). The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Herpes Labialis appearing as the primary indexed condition, and to 1 intervention - of which valacyclovir+clobetasol gel is the first listed.
NCT00297011 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.
Frequently Asked Questions
What is clinical trial NCT00297011 about?
NCT00297011 is a clinical study titled "Valacyclovir+Temovate Gel for the Treatment of Herpes Labialis". A randomized study comparing the combination of valacyclovir and temovate gel (clobetasol gel) versus placebo for the treatment of recurrent herpes labialis (cold sores).
What is the current status of trial NCT00297011?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 2004-09. Estimated completion is 2008-01.
What conditions does trial NCT00297011 study?
This clinical trial studies the following conditions: Herpes Labialis.
What interventions are being tested in trial NCT00297011?
The interventions under investigation include: valacyclovir+clobetasol gel (DRUG).
Who is sponsoring clinical trial NCT00297011?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00297011 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Herpes Labialis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Pharmacokinetics of Famciclovir Single 1500 mg Dose in Adolescents With Recurrent Herpes Labialis
COMPLETED · Phase 2
-
Iontophoretic Application of Acyclovir Cream to Treat Recurrent Herpes Labialis
COMPLETED · Phase 2
-
Viral Infections in Healthy and Immunocompromised Hosts
RECRUITING
-
Phase 3 Clinical Study for the Treatment of Cold Sore
COMPLETED · Phase 3
-
Open Label Safety Study of Xerese Cream in the Treatment of Recurrent Herpes Labialis in Children 6-11 Years Old
COMPLETED · Phase 3
-
Efficacy and Safety Study of ME-609 and Acyclovir for Treatment of Herpes Simplex Labialis
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.